Comparison of effectiveness and safety between uninterrupted direct oral anticoagulants with and without switching to dabigatran in atrial fibrillation ablation.

ABSTRACT:

Introduction

Recent studies have demonstrated the feasibility of uninterrupted direct oral anticoagulants (DOACs) with a temporary switch to dabigatran ("dabigatran bridge") for atrial fibrillation (AF) ablation. We compared the effectiveness and safety between uninterrupted DOACs with and without the "dabigatran bridge" in patients taking factor Xa inhibitors.

Methods

AF patients on factor Xa inhibitors (rivaroxaban/apixaban/edoxaban) undergoing catheter ablation were eligible (n = 348). Brain MRI was performed within 2 days after the procedure to detect silent cerebral events (SCEs). Rivaroxaban/apixaban/edoxaban were uninterruptedly used in 153 patients (Group 1); these DOACs were switched to dabigatran on the day of AF ablation in 195 patients (Group 2). After propensity

SUBMITTER: Harada M 

PROVIDER: S-EPMC7280006 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature